UroGen Pharma Ltd. Interest and Other Income
UroGen Pharma Ltd. (URGN) reported Interest and Other Income of $599.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:InterestAndOtherIncome · last filed 2026-08-05
- UroGen Pharma Ltd. interest and other income for the quarter ending 2026-06-30 was $599.00K, a 53.89% decline year-over-year.
- UroGen Pharma Ltd. interest and other income for the quarter ending 2026-03-31 was $608.00K, a 71.24% decline year-over-year.
- UroGen Pharma Ltd. interest and other income for the quarter ending 2025-12-31 was $903.00K, a 67.16% decline year-over-year.
- UroGen Pharma Ltd. interest and other income for the quarter ending 2025-09-30 was $979.00K, a 62.33% decline year-over-year.
- UroGen Pharma Ltd. interest and other income for fiscal 2025 was $5.29M, a 38.94% decline from fiscal 2024.
- UroGen Pharma Ltd. interest and other income for fiscal 2024 was $8.67M, a 149.27% increase from fiscal 2023.
- UroGen Pharma Ltd. interest and other income for fiscal 2023 was $3.48M, a 244.46% increase from fiscal 2022.
- UroGen Pharma Ltd. interest and other income for fiscal 2022 was $1.01M, a 376.42% increase from fiscal 2021.
| Period end | Interest and Other Income 3 month | Interest and Other Income 6 month | Interest and Other Income 9 month | Interest and Other Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $599.00K 10-Q · filed 2026-08-05 | $1.21M 10-Q · filed 2026-08-05 | $2.11M derived: sum of 3 quarters · filed 2026-08-05 | $3.09M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $608.00K 10-Q · filed 2026-05-06 | $1.51M derived: sum of 2 quarters · filed 2026-05-06 | $2.49M derived: sum of 3 quarters · filed 2026-05-06 | $3.79M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $903.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.88M derived: sum of 2 quarters · filed 2026-03-02 | $3.18M derived: sum of 3 quarters · filed 2026-08-05 | $5.29M 10-K · filed 2026-03-02 |
| 2025-09-30 | $979.00K 10-Q · filed 2025-11-06 | $2.28M derived: sum of 2 quarters · filed 2026-08-05 | $4.39M 10-Q · filed 2025-11-06 | $7.14M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.30M 10-Q · filed 2026-08-05 | $3.41M 10-Q · filed 2026-08-05 | $6.16M derived: sum of 3 quarters · filed 2026-08-05 | $8.76M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $2.11M 10-Q · filed 2026-05-06 | $4.86M derived: sum of 2 quarters · filed 2026-05-06 | $7.46M derived: sum of 3 quarters · filed 2026-05-06 | $9.17M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $5.35M derived: sum of 2 quarters · filed 2026-03-02 | $7.06M derived: sum of 3 quarters · filed 2026-03-02 | $8.67M 10-K · filed 2026-03-02 |
| 2024-09-30 | $2.60M 10-Q · filed 2025-11-06 | $4.31M derived: sum of 2 quarters · filed 2025-11-06 | $5.92M 10-Q · filed 2025-11-06 | $7.46M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.71M 10-Q · filed 2025-08-07 | $3.32M 10-Q · filed 2025-08-07 | $4.86M derived: sum of 3 quarters · filed 2025-08-07 | $5.77M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.61M 10-Q · filed 2025-05-12 | $3.15M derived: sum of 2 quarters · filed 2025-05-12 | $4.06M derived: sum of 3 quarters · filed 2025-05-12 | $4.46M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $2.44M derived: sum of 2 quarters · filed 2025-03-10 | $2.85M derived: sum of 3 quarters · filed 2025-03-10 | $3.48M 10-K · filed 2025-03-10 |
| 2023-09-30 | $906.00K 10-Q · filed 2024-11-06 | $1.31M derived: sum of 2 quarters · filed 2024-11-06 | $1.94M 10-Q · filed 2024-11-06 | $2.35M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $405.00K 10-Q · filed 2024-08-13 | $1.03M 10-Q · filed 2024-08-13 | $1.44M derived: sum of 3 quarters · filed 2024-08-13 | $1.92M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $630.00K 10-Q · filed 2024-05-13 | $1.04M derived: sum of 2 quarters · filed 2024-05-13 | $1.51M derived: sum of 3 quarters · filed 2024-05-13 | $1.64M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $406.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $884.00K derived: sum of 2 quarters · filed 2024-03-14 | $1.01M derived: sum of 3 quarters · filed 2024-03-14 | $1.01M 10-K · filed 2024-03-14 |
| 2022-09-30 | $478.00K 10-Q · filed 2022-11-10 | $606.00K derived: sum of 2 quarters · filed 2022-11-10 | $604.00K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $128.00K 10-Q · filed 2022-08-11 | $126.00K 10-Q · filed 2022-08-11 | ||
| 2021-12-31 | -$57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $0.00 derived: sum of 2 quarters · filed 2023-03-24 | $33.00K derived: sum of 3 quarters · filed 2023-03-24 | $212.00K 10-K · filed 2023-03-24 |
| 2021-09-30 | $57.00K 10-Q · filed 2022-11-10 | $90.00K derived: sum of 2 quarters · filed 2022-11-10 | $269.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $33.00K 10-Q · filed 2022-08-11 | $212.00K 10-Q · filed 2022-08-11 | ||
| 2018-03-31 | $358.00K 6-K · filed 2018-05-15 | |||
| 2017-03-31 | $121.00K 6-K · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |